Nabriva Therapeutics Appoints Dr David Chiswell as Chief Executive Officer

01-Apr-2009 - Austria

Nabriva Therapeutics has announced the appointment of Dr David Chiswell as its Chief Executive Officer. Dr Chiswell has been involved with Nabriva since its foundation, having served as Chairman of the Supervisory Board for the past three years.

Dr Chiswell is a highly experienced and respected business leader within the biotech community, having made significant contributions at board level to a number of biotech companies in Europe. He founded and led Cambridge Antibody Technology (CAT) from 1990 until 2002 (including as its CEO from 1996 to 2002). During this time, CAT raised £150m in equity finance, completed a number of strong corporate partnerships and developed Humira, the first billion dollar drug discovered by a European biotech company.

Since leaving CAT in 2002, Dr Chiswell has served on the boards of a number of emerging private biotech companies including: Arakis Ltd (sold to Sosei Co. Ltd in 2005); Non-executive Chairman of Arrow Therapeutics Ltd (sold to Astra Zeneca plc in 2007); Non-executive Chairman of Daniolabs Ltd (sold to Vastox plc in 2007); Non-Executive Chairman of Sosei 2004-2008. He is currently Chairman of Albireo Pharma, a position which he will retain.

During 2009, Nabriva will generate key human data for its two lead pleuromutilin-based antibiotics BC-3205 and BC-3781. Both compounds are being developed as both oral and intravenous treatments for life threatening infectious diseases caused in particular by multi-drug resistant (MDR) pathogens including methicillin resistant Staphylococcus aureus (MRSA) and MDR Streptococcus pneumoniae. The Company anticipates that at least one program will progress through phase II during 2010. The company also has a topical pleuromutilin antibiotic, BC-7013, in phase I clinical development.

Dr Chiswell succeeds George Golumbeski who has left the Company.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances